多西紫杉醇联合替吉奥治疗乳腺癌的效果

目的观察多西紫杉醇联合替吉奥方案对蒽环类耐药的晚期乳腺癌患者的临床疗效及毒副作用.方法：26 例既往接受过蒽环类等药物化疗的晚期乳腺癌患者,采用多西紫杉醇（75mg/m2 静滴 d1）联合替吉奥（80mg/m2/天,分2 次口服,d1～d14）化疗2～4 周期,每3 周重复一次,行2 周期治疗后判定疗效和毒副反应.结果：26 例中CR 5 例,PR 10 例,SD 6 例,PD 5 例,有效率为57.7%,临床获益率为80.8%.结论：国产多西紫杉醇联合替吉奥治疗蒽环类耐药的晚期乳腺癌有较好疗效,值得临床进一步研究.

objective：to observe the docetaxel combined for gonow scheme of anthracycline-based drug resistance in patients with advanced breast cancer clinical efficacy and sideeffects. Methods：26 cases ever received anthracycline-based drugs such as chemotherapy in patients with advanced breast cancer, with docetaxel static drop d1 （75 mg/m2） for gonow（80 mg/m2 / day, two points of oral, d1 - d14） 2 - 4 cycles of chemotherapy, once every 3 Zhou Chongfu, line 2 cycle judge curative effect and adverse reaction after treatment.Results：26 cases of CR in 5 cases, 10 cases of PR, SD 6 cases, 5 cases with PD, the effective rate was 57.7%, the clinical benefit rate was 80.8%. Conclusion：domestic docetaxelcombined for gonow anthracycline-based resistant treatment of advanced breast cancer has good curative effect, worth clinical research further.